CN100402074C - 一种促进痔瘘术后创面愈合的中药膏剂及其制备方法 - Google Patents
一种促进痔瘘术后创面愈合的中药膏剂及其制备方法 Download PDFInfo
- Publication number
- CN100402074C CN100402074C CNB2006100438187A CN200610043818A CN100402074C CN 100402074 C CN100402074 C CN 100402074C CN B2006100438187 A CNB2006100438187 A CN B2006100438187A CN 200610043818 A CN200610043818 A CN 200610043818A CN 100402074 C CN100402074 C CN 100402074C
- Authority
- CN
- China
- Prior art keywords
- group
- chinese medicine
- medicine
- processed
- calculus bovis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 33
- 230000029663 wound healing Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 208000004680 Rectal Fistula Diseases 0.000 title claims description 31
- 206010002156 anal fistula Diseases 0.000 title claims description 31
- 230000001737 promoting effect Effects 0.000 title abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 101
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 31
- 241001161070 Calomela Species 0.000 claims abstract description 21
- 238000012545 processing Methods 0.000 claims abstract description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 22
- 239000011812 mixed powder Substances 0.000 claims description 21
- 239000009286 sanguis draxonis Substances 0.000 claims description 21
- 241000717739 Boswellia sacra Species 0.000 claims description 18
- 239000004863 Frankincense Substances 0.000 claims description 18
- 244000293323 Cosmos caudatus Species 0.000 claims description 17
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 17
- 241001057584 Myrrha Species 0.000 claims description 17
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 239000004570 mortar (masonry) Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000003871 white petrolatum Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 41
- 206010052428 Wound Diseases 0.000 abstract description 31
- 208000027418 Wounds and injury Diseases 0.000 abstract description 31
- 208000014617 hemorrhoid Diseases 0.000 abstract description 19
- 230000017531 blood circulation Effects 0.000 abstract description 6
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract description 6
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract description 6
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract description 5
- 229940116229 borneol Drugs 0.000 abstract description 5
- 239000000835 fiber Substances 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 230000008030 elimination Effects 0.000 abstract description 3
- 238000003379 elimination reaction Methods 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 235000000177 Indigofera tinctoria Nutrition 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000003102 growth factor Substances 0.000 abstract description 2
- 229940097275 indigo Drugs 0.000 abstract description 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 abstract description 2
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 206010016717 Fistula Diseases 0.000 abstract 3
- 230000003890 fistula Effects 0.000 abstract 3
- 230000001133 acceleration Effects 0.000 abstract 2
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 241000935235 Fritillaria meleagris Species 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 241000238371 Sepiidae Species 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 229940105847 calamine Drugs 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000009136 dragon's blood Substances 0.000 abstract 1
- 229910052602 gypsum Inorganic materials 0.000 abstract 1
- 239000010440 gypsum Substances 0.000 abstract 1
- 229910052864 hemimorphite Inorganic materials 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 238000005215 recombination Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 235000014692 zinc oxide Nutrition 0.000 abstract 1
- 239000011787 zinc oxide Substances 0.000 abstract 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 19
- 230000036407 pain Effects 0.000 description 19
- 230000035876 healing Effects 0.000 description 17
- 206010040943 Skin Ulcer Diseases 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 231100000019 skin ulcer Toxicity 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000008961 swelling Effects 0.000 description 11
- 206010042674 Swelling Diseases 0.000 description 10
- 238000005469 granulation Methods 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 9
- 208000025865 Ulcer Diseases 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 230000036461 convulsion Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000002980 postoperative effect Effects 0.000 description 8
- 206010010904 Convulsion Diseases 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 6
- 208000033809 Suppuration Diseases 0.000 description 6
- 206010040872 skin infection Diseases 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 241000475481 Nebula Species 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 239000002390 adhesive tape Substances 0.000 description 4
- 208000002399 aphthous stomatitis Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 3
- 206010002153 Anal fissure Diseases 0.000 description 3
- 208000016583 Anus disease Diseases 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 240000001624 Espostoa lanata Species 0.000 description 3
- 235000009161 Espostoa lanata Nutrition 0.000 description 3
- 208000009531 Fissure in Ano Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 229920000153 Povidone-iodine Polymers 0.000 description 3
- 208000002847 Surgical Wound Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 210000003026 hypopharynx Anatomy 0.000 description 3
- 229960001621 povidone-iodine Drugs 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010048946 Anal abscess Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000208229 Burseraceae Species 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000201295 Euphrasia Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000382362 Persicaria tinctoria Species 0.000 description 2
- 241000879903 Pteria Species 0.000 description 2
- 241001663378 Sepiella maindroni Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009172 bursting Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- -1 cholochrome Chemical compound 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000002692 epidural anesthesia Methods 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 229910000010 zinc carbonate Inorganic materials 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- DSSRNNGLLCLIPR-QHGLUPRGSA-N (2s)-2-amino-n-(1,2,3,4-tetrahydronaphthalen-2-yl)propanamide Chemical compound C1=CC=C2CC(NC(=O)[C@@H](N)C)CCC2=C1 DSSRNNGLLCLIPR-QHGLUPRGSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CJGSNPCDEYCMDA-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-4-fluoro-6-methylphenol Chemical compound CN(C)CC1=CC(F)=CC(C)=C1O CJGSNPCDEYCMDA-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- PFCVZKFJHRCLCC-MTYXOXLRSA-N Alphitolic acid Natural products CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@@H](CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O PFCVZKFJHRCLCC-MTYXOXLRSA-N 0.000 description 1
- 206010065360 Anal prolapse Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- 241001608538 Boswellia Species 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 229910021532 Calcite Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000382825 Cristaria plicata Species 0.000 description 1
- 241001172538 Daemonorops draco Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000123611 Dipterocarpaceae Species 0.000 description 1
- UFJPCTSKTPSJTK-UHFFFAOYSA-N Dryobalanone Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC(C(O)(CO)CCC=C(C)C)C4CCC3C21C UFJPCTSKTPSJTK-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000605372 Fritillaria Species 0.000 description 1
- 241001644297 Fritillaria delavayi Species 0.000 description 1
- 241001644295 Fritillaria przewalskii Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241000382840 Hyriopsis cumingii Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OVHUAFPHYGFWPY-UHFFFAOYSA-N Imperialin Natural products CC1CN2CC3C(CCC4C3CC5C4CC(=O)C6CC(O)CCC56C)CC2C(C)(O)C1 OVHUAFPHYGFWPY-UHFFFAOYSA-N 0.000 description 1
- IQDIERHFZVCNRZ-LZOOXBQUSA-N Imperialine Natural products O=C1[C@@H]2[C@@](C)([C@@H]3[C@H]([C@@H]4[C@H]([C@H]5[C@H]([C@@](O)(C)[C@H]6N(C[C@@H](C)CC6)C5)CC4)C3)C1)CC[C@@H](O)C2 IQDIERHFZVCNRZ-LZOOXBQUSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- DTGKSKDOIYIVQL-MRTMQBJTSA-N Isoborneol Natural products C1C[C@@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-MRTMQBJTSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241001502129 Mullus Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- PSZDOEIIIJFCFE-UHFFFAOYSA-N Oleanolic alcohol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C)(C)CC5C4=CCC3C21C PSZDOEIIIJFCFE-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- 235000014643 Orbignya martiana Nutrition 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241001441745 Sepia esculenta Species 0.000 description 1
- IQDIERHFZVCNRZ-LRCDAWNTSA-N Sipeimine Chemical compound C([C@@H]1C(=O)C[C@H]2[C@@H]3CC[C@H]4[C@]5(C)O)[C@@H](O)CC[C@]1(C)[C@H]2C[C@H]3[C@@H]4CN1[C@H]5CC[C@H](C)C1 IQDIERHFZVCNRZ-LRCDAWNTSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000257673 Strobilanthes cusia Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 241000217379 Unionidae Species 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical group 0.000 description 1
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229910052925 anhydrite Inorganic materials 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 229910001748 carbonate mineral Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 201000010582 ecthyma Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- PSZDOEIIIJFCFE-OSQDELBUSA-N erythrodiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PSZDOEIIIJFCFE-OSQDELBUSA-N 0.000 description 1
- HTZRWCSRPTWJCT-UHFFFAOYSA-N erythrodiol Natural products CC1(C)CCC2(CO)CCC3C(CCC4C3(C)CCC5C(C)(C)C(O)CCC45C)C2C1 HTZRWCSRPTWJCT-UHFFFAOYSA-N 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- HIDAYMRWVVNXAO-UHFFFAOYSA-N imperialone Natural products CC1(O)C2CCC3C4CC(=O)C5CC(=O)CCC5(C)C4CC3C2CN2C1CCC(C)C2 HIDAYMRWVVNXAO-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种促进痔瘘术后创面愈合的中药膏剂及其制备方法,它由龙骨、炉甘石、煅石膏、琥珀、海螵蛸、制乳香、制没药、人中白、川贝母、珍珠、青黛、牛黄、人工牛黄、轻粉、血竭、冰片经合理配比、科学加工而成。该促进痔瘘术后创面愈合的中药膏剂,能与手术根治配合使用,并能从改善微循环、促进创面静脉回流分开、起动吞噬系统、消灭异物、控制感染、改善血流动力、抗血栓形成、增加创面局部生长因子的有效浓度、加速胶原纤维的合成及细胞在创面处的增殖、加速创面胶原纤维及细胞的重新组合等方面入手,致使手术创面快速愈合,应用效果明显,可广泛用于痔瘘术后患者。
Description
技术领域
本发明属于一种中药膏剂,特别是一种促进痔瘘术后创面愈合的中药膏剂及其制备方法。
背景技术
痔瘘是一种影响人类健康的常见病,发病率极高,在正常人群中,总发病率约占87%,其病源多因肝、胃湿热下注,造成大肠肛门区域有湿毒浊气,久之形成病灶。在便秘期间受压力或长期静坐时的外部压力的影响,可进一步恶化或裂开,造成出血,甚至引起感染出现并发症,加剧恶化。对于痔瘘的治疗有多种方法,如手术、外洗、内服、外服、电疗等。服用西药治疗,一般疗效较慢,也不能根治;手术治疗一般疗效较快,但术后创面都存在一定的延期愈合和不愈合的倾向。目前采用中药组合物治疗的药方也较多,如有的以麝香、马钱子为主要成分配制的中药,此种中药对高血压患者和孕妇均不能服用;还有的以紫草、黄柏、黄芩、虎杖、甘草、地榆、冰片为主要原料,作成软膏,对病灶处灌注使用,此药虽有较好的疗效,但不能与手术治疗相结合,用于促伤口愈合,因此,治愈仍较慢。
发明内容
本发明的目的在于提供一种能与手术治疗相结合,并能抗感染、消水肿、减少创面组织渗液、促进伤口快速愈合,不仅具有疗效快的效果,而且还具有根治效果的促进痔瘘术后创面愈合的中药膏剂。
本发明的另一目的在于提供一种如上所述的促进痔瘘术后创面愈合的中药膏剂的制备方法。
为达到以上目的,本发明所采用的技术方案是:该促进痔瘘术后创面愈合的中药膏剂,其特征在于它由下述重量份配比的中药原料制成:龙骨220-260g,炉甘石90-110g,煅石膏110-134g,琥珀20-40g,海螵蛸110-136g,制乳香30-60g,制没药30-60g,人中白60-80g,川贝母20-30g,珍珠2-6g,青黛70-80g,牛黄2-6g,人工牛黄6-10g,轻粉38-60g,血竭40-60g,冰片9-11g。
该促进痔瘘术后创面愈合的中药膏剂,其中药原料的重量份配比为:龙骨243g,炉甘石97g,煅石膏121g,琥珀29g,海螵蛸122g,制乳香48g,制没药48g,人中白73g,川贝母24g,珍珠4g,青黛73g,牛黄4g,人工牛黄8g,轻粉48g,血竭48g,冰片10g。
如上所述的促进痔瘘术后创面愈合的中药膏剂的制备方法,其生产步骤为:
(1)、先将龙骨、炉甘石、石膏、珍珠、乳香、没药分别按2002年版《山东省中药炮制规范》进行炮制;
(2)、按以上配合比例称量龙骨220-260g,炉甘石90-110g,煅石膏110-140g,琥珀20-40g,海螵蛸110-136g,制乳香30-60g,制没药30-60g,人中白60-80g,川贝母20-30g,珍珠2-6g,青黛70-80g,牛黄2-6g,人工牛黄6-10g,轻粉38-60g,血竭40-60g,冰片9-11g,并进行分组,将龙骨、炉甘石、煅石膏、琥珀、海螵蛸、制乳香、制没药、人中白、川贝母、珍珠,作为第一组药物,将青黛、牛黄、人工牛黄作为第二组药物备用,将轻粉、血竭、冰片单独称量好作为第三组药物备用;
(3)、先对称量好的第一组药物进行烘干、粉碎、过100-120目筛、混匀成第一组药物混合粉;对称量好的第二组药物按研磨混合法,置乳钵中,边研磨边混合,过100-120目筛,混匀,成第二组药物混合粉;对第一组药物混合粉和第二组药物混合粉先采用打底套色法混合,再采用等量递增法混合,直至将第一组药物混合粉加完为止,再过100-120目筛,反复混匀,得第一、二组药物混合粉;轻粉、血竭、冰片单研过100目筛,成第三组药物粉,因第三组药物为易挥发药,故单包备用;
(4)、称取白凡士林8000g、羊毛脂1000g、二甲基亚砜10g,作为基质,将基质放蒸发皿中、水浴加热溶化,在保持温度65-75℃范围内时,一边不断搅拌,一边缓缓加入以上制取的第一、二组药物混合粉,当温度上升到100℃时,保持15-20分钟,停止加热降温,对温度降至30℃-40℃时,再将易挥发的第三组药物粉中的轻粉、血竭粉、冰片粉分别缓缓加入,搅拌均匀即可制得该中药膏剂,最后可分装。
该中药膏剂的药理为:
龙骨为古代哺乳动物(如三趾马、犀类、鹿类、牛类、象类等)的骨骼化石。除去泥沙杂质,贮于干燥处,用时打碎,生用或煅用。性味归经,甘、涩、微寒,归心、肝经。具有平肝潜阳、镇静安神、收敛固涩的功效,锻龙骨研末外用,有吸湿敛疮作用。
炉甘石为碳酸盐类矿物方解石族菱锌矿,主含碳酸锌(ZnCo3)。采挖后洗净、晒干、除去杂石。该药物体轻、易碎,气微,味微涩。性味与归经:甘、平、归胃经。具有解毒明目退翳,收湿止痒敛疮之功效。用于目赤肿痛、眼缘赤烂、翳膜胬肉、溃疡不敛、浓水淋漓、湿疮、皮肤瘙痒。另有资料表明:炉甘石有一定的抑菌作用,对健康组织和新生上皮组织有保护作用,用药后能很快使炎症局限,并能促使突出创面的肉芽及坏死组织液化,使创面清洁平整,易于修复,收到腐尽肌生的效果。该中药膏剂中的炉甘石具有收敛抑制分泌或部分吸收创面分泌液、减少化脓、保护创面的作用。
煅石膏为硫酸盐类矿物硬石膏族石膏,主要含水硫酸钙(CaSo4·2H2。),采挖后,除去泥沙及杂石。该药物甘、辛、大寒、归肺、胃经。具有清热泻火、除烦止渴之功效。主要用于外感热病、高热烦渴、肺热喘咳、胃炕盛、头痛牙痛。煅石膏能收敛粘膜减少分泌,用于疮疡溃烂而不敛,湿疹侵淫及水火烫伤等。
琥珀为古代松科植物埋藏于地下,经年久凝结转化而成的化石样物质。甘、平,归心、肝、膀胱经。具有镇惊安神、活血化瘀之功效。主要用于心神不宁、惊风、癫狂、痫症、血淋、石淋热淋。尤宜于治疗疮痛肿痛、瘰病、瘿瘤、金疮外伤等疾患。
海螵蛸为乌鱼则科动物无针乌贼sepiella maind roni deRochebrune或金乌贼sepia esculenta Hoyle的干燥内壳。成、涩、温。归脾、肾经。具有收敛止血、涩精止带、制酸敛疮之功效。主要用于溃疡病、胃酸过多、吐血衄血、崩漏便血遗精便血、胃痛吞酸;外治损伤出血,疮多脓汁。能中和胃酸、促进溃疡面愈合、改变胃内容物PH值、降低胃蛋白酶活性、促进骨折愈合、缩短骨折愈合时间、促进纤维细胞和成骨细胞增生与骨化。
制乳香为橄榄科小乔木卡氏乳香树及其同属、植物皮部渗出的树脂制用。辛、苦、温。归肝、心、脾经。具有活血止痛、锁痛、消肿生肌之功效。常用于瘀血阻滞的诸痛下(如心腹瘀痛,痛经以及跌打损伤,痈疽疼痛及风湿痹痛等症)、疮疡溃后久不收回,口服制乳香后能促进多核白细胞增加,以吞噬死亡的血细胞,改善新陈代谢,从而有消炎作用,并可用来防腐及消除口臭,加速炎症渗出排泄、吸收、促进伤口愈合。
制没药为橄榄科灌木或乔木不药树或其他同属植物皮部渗出的油胶树脂制用。该药物辛、苦、平。归心、肝、脾经。具有活血止痛、消肿生肌之功效。主要用于治跌打损伤淤滞肿痛、外科痈肿痛、疮疡溃后久不收口,以及一切淤滞心腹诸痛。药理实验表明,对多种致病菌有不同程度的抑制作用;并防止斑块形成。
人中白:咸、平、无毒,能泻肝火、三焦火并膀胱火、降火,主要作用是消淤血、清热解毒、防腐生肌、止血疗口疮、咽喉、口齿生疮,主治鹅口疮、化脓性扁桃腺炎、口腔溃疡等。
川贝母为百合科植物川贝母Fritiuaria cirrhosa D.Don、暗紫贝母Fritillaria unibrac teataHsiao etk,c.Hsia、甘肃贝母FritillariaPrzewalskii Maxim,或梭砂贝母Fritillaria delavayi Fianch的干燥鳞基。前三者按性状不同分别习称“松贝”和“青贝”,后者习称“炉贝”。夏、秋二季或积雪融化时采控,除去须根,粗皮及泥沙,晒干或低温干燥。该药物苦、甘、微寒。归肺、心经。具有清热润肺、化痰止咳之功效。主要用于肺热燥咳、干咳少痰、阴虚劳嗽、咯痰带血。川贝母流浸膏,川贝母碱均有不同程度的祛痰作用;贝母总碱及非生物碱部分,均有镇咳作用;贝母总碱尚有抗溃疡作用。川贝碱有降压作用;西贝母碱亦能解痉;体外实验表明,川贝母有抑制大肠杆菌及黄色葡萄球菌的作用。
珍珠为珍珠贝壳动物马氏珍珠贝Pteria martensii(Dunker)蚌科动物三角帆蚌Hyriopsis cumingii(lea)或褶纹冠蚌Cristaria plicata(leach)等双壳类动物受刺激形成的珍珠。自动物体内取出,洗净,干燥。该药物甘、咸、寒。归心、肝经。具有安神定惊、明目消翳、解毒生肌之功效,主要用于惊悸失眠、惊风癫痫、目生云翳、疮疡不敛。心虚有热、则神气浮越;高热痰迷,则神志惊阙;肝虚有热,则目生翳障。即有解二经之热,又可滋二经之阴,而有养心安神,镇惊坠痰、明目去翳之功,所以阴虚阴盛之症两得其用。用于痈疽肿毒溃疡不敛,敷之能解毒生肌收口。内服外用,攻效并举。
青黛为爵床科植物马蓝Baphica canthus cusia(Nees)Bremek.蓼科植物蓼蓝Polygonum tinctorium Ai或十字花科植物菘蓝Isatisind igoticg Fort的叶茎叶经加工值得的干燥粉末或团块。该药物为深蓝色的粉末,体轻、易飞扬;或呈不规则多孔性的团块,用手搓捻即成细末。微有草腥味、味淡。咸、寒、归肝经。具有清热解毒、凉血定惊之功效。主要用于湿毒发斑、血热吐衄、胸痛咳血、疮、痄腮、喉痹、小儿惊痫;又常用于湿疮、湿疹、口舌咽喉溃疡。另有资料表明青黛乙醇浸液在体外对炭疽杆菌、肺炎杆菌、痢疾杆菌、霍乱孤菌、金色葡萄球菌和白色葡萄球菌等,皆有抑制作用。
牛黄为牛科动物牛Bog tqurus domesticus Gmelin干燥的胆结石,宰牛时,如发现有牛黄、即滤去胆汁,将中黄取出,除去外部薄膜、阴干。该药物甘、凉。归心,肝经。具有清心、豁痰、开窍、凉肝、息风、解毒之功效。主要用于热病神昏、中风痰迷、惊闲抽搐、癫痫发狂、咽喉肿痛,口舌生疮、痈肿疔疮。该药物含胆汁酸,胆汁色素,胆红素,胆甾醇,胆绿素,维生素D及多种氨基酸;亦含钠、钙、镁、铁、铜、磷及胡萝卜素及粘蛋白,脂肪酸及肽类成分。今有人工牛黄,系从牛胆汁或猪胆汁经人工提取加工制造而成,其性能、功效与天然牛黄相似,并被广泛采用,但功力不及天然牛黄;多用于咽喉肿痛、痈肿疮毒等热毒症。温热病、高热、神昏、抽搐者,仍以天然牛黄为宜。
轻粉为白色有光泽的鳞片状或雪花状结晶性粉末。无臭,几乎无味,遇光颜色缓缓变暗。辛、寒,有毒,归大肠、小肠经。外用可杀虫、攻毒、敛疮;内服可祛痰消积,外沿用于疥疮、顽癣、臁疮、梅毒、疮疡、湿疹,故尤宜于瘙痒性,创疡溃烂,脓水淋漓作痒等皮肤病。
血竭为棕榈科植物麒麟竭Daemonor ops draco Bl果实渗出的树脂经加工制成。研粉为砖红色、气微、味淡,在水中不溶,在热水中软化。性味与归经:甘、咸、平,归心、肝经。具有祛瘀定痛、生血生肌之功效。①用于外伤出血,溃疡不敛,外用有止血生肌敛疮之效。②用于跌打损伤、瘀血肿痛,有散瘀止痛功效。
冰片为龙脑香科植物龙脑香树脂的加工品,或龙脑香的树干经蒸馏冷却而得的结晶,称“龙脑冰片”。该药物辛、苦、微寒。归心、脾、肺经,具有开窍醒神、清热止痛之功效。主要用于热病神昏、痉厥、中风痰厥、气郁暴厥、中恶昏迷、目赤、口疮、咽喉肿痛,耳道流脓。龙脑冰片中含有旋龙脑,葎草烯、B一榄香烯、石竹烯等倍丰萜类成分和齐墩果酸、麦珠子酸、积雪草酸、龙脑香二醇酮、古柯二醇等二萜类成分。合成冰片主要含龙脑、异龙脑、樟脑等。天然冰片与合成冰片均有抑菌作用,并有促进神经胶质细胞的分裂和生长使用;对感觉神经有轻微的刺激作用而止痛;尚有温和的防腐作用。体外实验有抑制猪霍乱菌、大肠杆菌,金黄色葡萄球菌生长的作用。该药物具有祛腐生肌、镇痛消炎、杀菌止血、祛腐敛疮作用,适用于溃疡或术后创面未敛者。
该中药膏剂方中的血竭和血收口,制乳香、制没药活血止痛,消肿生肌,龙骨生肌收湿,轻粉长于攻疮毒,收湿敛疮,杀虫止痒,煅石膏收敛粘膜,减少分泌。海螵蛸收敛止血,敛疮排脓。青黛、牛黄、珍珠、冰片同具有清热解毒,散结消肿之功。诸药合用,具有清热解毒、活血化瘀、以促消散,清热托毒,以促进疮疡破溃排脓,祛腐敛疮,生肌之功效。
采用该促进痔瘘术后创面愈合的中药膏剂在小鼠身上作过对二甲苯致小鼠耳廓肿胀影响、对角叉菜胶致大鼠足趾肿胀影响及对小鼠热板镇痛影响的试验,证明该促进痔瘘术后创面愈合的中药膏剂对二甲苯致小鼠耳廓肿胀有明显的抑制作用;大鼠足趾肿痛率明显降低;对醋酸引起的腹痛有明显的抑制作用,小鼠扭体次数明显减少,试验中,未发现创面有刺激,未见过敏性发生。在抑菌试验中,通过对7个菌种123株菌的抗活性试验,观察了抗菌谱、菌株的敏感性分布,最小抑菌浓度,结果显示:该促进痔瘘术创面愈合的中药膏剂抗菌谱较广泛,对金黄色葡萄球菌、表皮葡萄球菌、枯草杆菌、绿脓杆菌、枸杞酸杆菌、变形杆菌、沙门氏菌、大肠杆菌、痢疾杆菌、肠球菌有不同程度的抑制作用,尤其对金黄色葡萄球菌抑制明显。
该促进痔瘘术后创面愈合的中药膏剂的使用方法为:首先对痔瘘进行手术治疗,术后第二天大便后,先用复方菁芥熏洗剂坐浴后,再用该促进痔瘘术后创面愈合的中药膏剂外敷手术创面,按创面大小外敷,直到敷满整个创面为止,纱布包扎,胶布固定,一般一天解大便后一次,不解大便,每天坐浴后也换一次,一天2次大便换2次,最后换药至手术创面全部愈合。
采用该促进痔瘘术后创面愈合的中药膏剂临床治疗166例,其中男79例,女87例;年龄12-70岁;病程1周至30年。环状混合痔20例,高位肛瘘30例,低位复杂性肛瘘50例,肛裂伴结缔组织性外痔26例,肛周脓肿一次切开根治40例。另有150例作对照,其性别、年龄、病程、病种及术后创面大小与观察组具有可比性。
从治疗对比结果看出:治疗组平均愈合天数为15.2天,对照组平均愈合天数21.0天,其中:治疗组中环状混合庤20例,愈合时间为12~17天,平均为14天,而对照组中的20例环状混合痔创口愈合时间15~21天,平均17天,治疗组比对照组平均提前愈合3天;治疗组中的高位肛瘘30例,愈合时间为20~31天,平均为24天,而对照组中的高位肛瘘28例,愈合时间为25-40天,平均32天,治疗组比对照组提前8天愈合;治疗组中的低位复杂性肛瘘50例,愈合时间为16~21天,平均19天,而对照组48例,愈合时间为18-23天,平均为22天,治疗组比对照组提前3天;治疗组中的肛裂拌结缔组织外痔26例,愈合时间为11~14天,平均12天,而对照组中20例愈合时间为14-17天,平均16天,治疗组比对照组提前4天愈合;治疗组中的肛周脓肿一次切开根治40例,愈合时间为12-42天,平均19天,而对照组中的34例愈合时间为20~52天,平均27天,治疗组比对照组平均提前8天。
治疗组与对照组创口愈合过程各阶段的持续天数比较表
创口愈合评定标准:
创口愈合按四个阶段:①凝血,防止血液进一步流失,保证创口处的机械强度;②炎症反应,是创口与静脉回流分开,启动吞噬系统消灭异物,控制感染;③肉芽组织形成,包括胶原的合成及细胞在创口处的增殖;④重组,包括胶原纤维及细胞的重新组合,以提高最大的机械强度。这四个阶段任何一个环节受到影响,都可能延长创口愈合时间。
本发明的有益效果在于:能与手术根治配合使用,并能从改善微循环、促进创面静脉回流分开、起动吞噬系统、消灭异物、控制感染、改善血流动力、抗血栓形成、增加创面局部生长因子的有效浓度、加速胶原纤维的合成及细胞在创面处的增殖、加速创面胶原纤维及细胞的重新组合等方面入手,致使手术创面快速愈合,应用效果明显。
实施方式
实施例1
按以下重量份配比称取中药原料:龙骨243g,炉甘石97g,煅石膏121g,琥珀29g,海螵蛸122g,制乳香48g,制没药48g,人中白73g,川贝母24g,珍珠4g,青黛73g,牛黄4g,人工牛黄8g,轻粉48g,血竭48g,冰片10g。
将称量好的以上中药原料按以下生产步骤制成促进痔瘘术后愈合的中药膏剂:
(1)首先将龙骨、炉甘石、石膏、珍珠、乳香、没药分别按2002年版《山东省中药炮制规范》进行炮制;
(2)将以上称量好的龙骨、炉甘石、煅石膏、琥珀、海螵蛸、制乳香、制没药、人中白、川贝母、珍珠作为第一组药物,将以上称量好的青黛、牛黄、人工牛黄作为第二组药物备用,将以上称量好的轻粉、血竭、冰片单独称量好作为第三组药物备用;
(3)、先对称量好的第一组药物进行烘干、粉碎、过110目筛、混匀成第一组药物混合粉;对称量好的第二组药物按研磨混合法,置乳钵中,边研磨边混合,过110目筛,混匀,成第二组药物混合粉;对第一组药物混合粉和第二组药物混合粉,先采用打底套色法混合,再采用等量递增法混合,直至将第一组药物混合粉加完为止,再过100目筛,反复混匀,得第一、二组药物混合粉;轻粉、血竭、冰片单研过100目筛,为第三组药物粉,并单包备用;
(4)、称取白凡士林8000g、羊毛脂1000g、二甲基亚砜10g,作为基质,将基质放蒸发皿中、水浴加热溶化,在保持温度70℃范围内时,一边不断搅拌,一边缓缓加入以上制取的第一、二组药物混合粉,当温度上升到100℃时,保持20分钟,停止加热降温,对温度降至38℃时,再将易挥发的第三组药物粉中的轻粉、血竭粉、冰片粉分别缓缓加入,搅拌均匀即可制得促进痔瘘术后创面愈合的中药膏剂,最后可分装。
典型病例
患者杨桂东,男,36岁,住院号10491,因肛门肿物胀痛伴肛内有肿物,自肛门脱出需要手托反复发作10年,加重2年。于2004年3月30日收入痔瘘科病房,入院后诊断;环状混合痔III期,在硬膜外麻醉下行外剥内扎术,术后每天换药2次,用碘伏棉球消毒后,创面挤满该促进痔瘘术后愈合的中药膏剂,纱布包扎,胶布固定,共半月后创面全愈,未见其它副作用。用此配方治疗类似病例共12例,均在12-16天内愈合,未见其他副作用。
实施例2
按以下重量份配比称取中药原料:龙骨220g,炉甘石106g,煅石膏130g,琥珀38g,海螵蛸110g,制乳香30g,制没药40g,人中白75g,川贝母28g,珍珠5g,青黛78g,牛黄5g,人工牛黄7g,轻粉60g,血竭58g,冰片10g。其生产步骤如实施例1,但粉碎后均采用100目筛。
典型病例
患者韩迎章,男,26岁,住院号:26690,因肛门周围有3个脓口,肿胀流脓水,反复发作5年,加重10天,于2005年8月12日收入痔瘘病房,入院诊断:低位复杂性肛瘘,在硬膜外麻醉下行分段开窗引流挂线术后,每天一次换药,换药时用碘伏棉球消毒后,创面挤满该中药膏剂,纱布包扎,胶布固定28天,创面全愈,未见其它副作用。用此配方治疗类似病例共有17例,均在17-21天内愈合,未见其它副作用。
实施例3
按以下重量份配比称取中药原料:龙骨260g,炉甘石90g,煅石膏110g,琥珀28g,海螵蛸110g,制乳香30g,制没药35g,人中白80g,川贝母30g,珍珠5g,青黛80g,牛黄5g,人工牛黄7g,轻粉60g,血竭60g,冰片10g。其生产步骤如实施例1,但粉碎后均采用100目筛。
典型病例
患者亓敏,女,24岁,住院号24130,于2005年5月13日收入痔瘘科病房,诊断为肛裂伴结缔组织性外痔,经手术治疗后,每天换药2次,用碘伏棉球消毒后,创面挤满该促进痔瘘术后愈合的中药膏剂,纱布包扎,胶布固定13天后创面全愈,未见其它副作用。用此配方治疗类似病例共10例,均在11~14天内愈合,未见其他副作用。
Claims (3)
1.一种促进痔瘘术后创面愈合的中药膏剂,其特征在于它由下述重量份配比的中药原料制成:龙骨220-260g,炉甘石90-110g,煅石膏110-134g,琥珀20-40g,海螵蛸110-136g,制乳香30-60g,制没药30-60g,人中白60-80g,川贝母20-30g,珍珠2-6g,青黛70-80g,牛黄2-6g,人工牛黄6-10g,轻粉38-60g,血竭40-60g,冰片9-11g。
2.根据权利要求1所述的促进痔瘘术后创面愈合的中药膏剂,其特征在于它的中药原料重量份配比为:龙骨243g,炉甘石97g,煅石膏121g,琥珀29g,海螵蛸122g,制乳香48g,制没药48g,人中白73g,川贝母24g,珍珠4g,青黛73g,牛黄4g,人工牛黄8g,轻粉48g,血竭48g,冰片10g。
3.如权利要求1所述的促进痔瘘术后创面愈合的中药膏剂的制备方法,其特征在于其生产步骤为:
(1)、先将龙骨、炉甘石、石膏、珍珠、乳香、没药分别按2002年版《山东省中药炮制规范》进行炮制;
(2)、按以上配合比例称量龙骨220-260g,炉甘石90-110g,煅石膏110-140g,琥珀20-40g,海螵蛸110-136g,制乳香30-60g,制没药30-60g,人中白60-80g,川贝母20-30g,珍珠2-6g,青黛70-80g,牛黄2-6g,人工牛黄6-10g,轻粉38-60g,血竭40-60g,冰片9-11g,并进行分组,将龙骨、炉甘石、煅石膏、琥珀、海螵蛸、制乳香、制没药、人中白、川贝母、珍珠,作为第一组药物,将青黛、牛黄、人工牛黄作为第二组药物备用,将轻粉、血竭、冰片单独称量好作为第三组药物备用;
(3)、先对称量好的第一组药物进行烘干、粉碎、过100-120目筛、混匀成第一组药物混合粉;对称量好的第二组药物按研磨混合法,置乳钵中,边研磨边混合,过100-120目筛,混匀,成第二组药物混合粉;对第一组药物混合粉和第二组药物混合粉,先采用打底套色法混合,再采用等量递增法混合,直到将第一组药物混合粉加完为止,再过100-120目筛,反复混匀,得第一、二组药物混合粉;轻粉、血竭、冰片单研过100目筛,成第三组药物粉;
(4)、称取白凡士林8000g、羊毛脂1000g、二甲基亚砜10g,作为基质,将基质放蒸发皿中、水浴加热溶化,在保持温度65-75℃范围内时,一边不断搅拌,一边缓缓加入以上制取的第一、二组药物混合粉,当温度上升到100℃时,保持15-20分钟,停止加热降温,对温度降至30℃-40℃时,再将易挥发的第三组药物粉中轻粉、血竭粉、冰片粉分别缓缓加入,搅拌均匀即可制得该中药膏剂,最后可分装。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100438187A CN100402074C (zh) | 2006-04-19 | 2006-04-19 | 一种促进痔瘘术后创面愈合的中药膏剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100438187A CN100402074C (zh) | 2006-04-19 | 2006-04-19 | 一种促进痔瘘术后创面愈合的中药膏剂及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1876085A CN1876085A (zh) | 2006-12-13 |
| CN100402074C true CN100402074C (zh) | 2008-07-16 |
Family
ID=37508754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100438187A Expired - Fee Related CN100402074C (zh) | 2006-04-19 | 2006-04-19 | 一种促进痔瘘术后创面愈合的中药膏剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100402074C (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103961690A (zh) * | 2014-05-25 | 2014-08-06 | 张勇 | 一种治疗褥疮的外用药膏及制备方法 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102068577B (zh) * | 2011-01-05 | 2012-09-26 | 王广志 | 一种中药组合物及其应用 |
| CN102198205B (zh) * | 2011-04-28 | 2012-10-10 | 上海市金山区中心医院枫泾分院 | 敛痔散及其制备方法 |
| CN105687846A (zh) * | 2016-03-11 | 2016-06-22 | 张雪燕 | 一种治疗痔瘘术后并发症的药物组合物及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1183950C (zh) * | 2003-04-16 | 2005-01-12 | 吉林敖东延边药业股份有限公司 | 治疗烧伤的中药制剂 |
| CN1615969A (zh) * | 2004-09-15 | 2005-05-18 | 史敬杰 | 一种治疗巴氏囊肿、疖、疔、疮、痈的中药制剂拔毒膏 |
-
2006
- 2006-04-19 CN CNB2006100438187A patent/CN100402074C/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1183950C (zh) * | 2003-04-16 | 2005-01-12 | 吉林敖东延边药业股份有限公司 | 治疗烧伤的中药制剂 |
| CN1615969A (zh) * | 2004-09-15 | 2005-05-18 | 史敬杰 | 一种治疗巴氏囊肿、疖、疔、疮、痈的中药制剂拔毒膏 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103961690A (zh) * | 2014-05-25 | 2014-08-06 | 张勇 | 一种治疗褥疮的外用药膏及制备方法 |
| CN103961690B (zh) * | 2014-05-25 | 2016-01-20 | 张勇 | 一种治疗褥疮的外用药膏及制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1876085A (zh) | 2006-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101049466B (zh) | 治疗烧烫伤的中草药膏及其制备方法 | |
| CN103230491A (zh) | 一种治疗痔疮的内服和外用组合苗药及其制备方法 | |
| CN100402074C (zh) | 一种促进痔瘘术后创面愈合的中药膏剂及其制备方法 | |
| CN106474245A (zh) | 一种治疗大疱性表皮松解症的中药 | |
| CN105168091A (zh) | 一种祛红血丝面膜粉及其制备方法 | |
| CN105343271A (zh) | 一种治疗脚气的药物及其制备方法 | |
| CN101658607A (zh) | 皮肌再生药用纱布及其制备方法 | |
| CN101049353A (zh) | 一种治疗脚气的药物洗液 | |
| CN109045204A (zh) | 一种治疗烧伤和烫伤的中药液及其制备方法 | |
| CN100350934C (zh) | 一种白癜消中药组合物及其制备方法 | |
| CN1068785C (zh) | 一种用于治疗烫伤、烧伤、皮肤溃疡等疾病的外用中成药 | |
| CN110403995B (zh) | 治疗浅静脉炎作用的中药组合物及制备、使用方法和应用 | |
| WO2022097105A1 (en) | Burn ointment using herbal compounds to repair a variety of infectious wounds | |
| CN102688368B (zh) | 一种用于治疗外伤止血或顽固性溃疡的中药 | |
| CN1199669C (zh) | 一种治疗宫颈炎的药物及制备方法 | |
| CN104623304A (zh) | 一种治疗湿热毒蕴型慢性皮肤溃疡的洗剂及其制备方法 | |
| CN105250525A (zh) | 一种治疗糖尿病足的中药洗剂及其制备方法 | |
| CN105250712A (zh) | 一种治疗褥疮的中药组合物 | |
| CN103816268B (zh) | 一种治疗烧烫伤的中药软膏及其制造方法 | |
| CN109464569A (zh) | 一种治疗烧伤的中药组合物、药膏及其制备方法 | |
| CN106798364A (zh) | 一种冻疮防治手套衬布 | |
| CN105125926A (zh) | 用于治疗烧烫伤的药粉及制备方法 | |
| CN102846778B (zh) | 一种治疗烧烫伤的中药及其制备方法 | |
| CN103585374A (zh) | 一种治疗灰指甲的药膏 | |
| CN106039179A (zh) | 一种祛痘中药制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080716 |